Galectin Therapeutics Investigated for Securities Fraud by Pomerantz LLP.

Pomerantz LLP is investigating claims on behalf of Galectin Therapeutics Inc. investors, alleging securities fraud or unlawful business practices by the company and its officers/directors. The investigation concerns the development program for belapectin, a galectin-3 inhibitor, after the FDA provided a written response to Galectin's Type C meeting request. Investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.